Literature DB >> 7543306

Induction of apoptosis in human eosinophils by anti-Fas antibody treatment in vitro.

K Matsumoto1, R P Schleimer, H Saito, Y Iikura, B S Bochner.   

Abstract

Fas antigen (CD95) can induce apoptosis of cells such as lymphocytes and neutrophils. To determine whether Fas antigen is involved in eosinophil apoptosis, we examined its expression and function on eosinophils in vitro. Purified human eosinophils expressed low but consistently detectable levels of Fas antigen. Culture of eosinophils in up to 10 ng/mL interleukin-5 (IL-5) prolonged eosinophil survival; incorporation of 1 to 1,000 ng/mL Fas antibody led to significant reductions in IL-5-induced eosinophil viability after 48 to 72 hours of culture. Reductions in survival could not be overcome by IL-5 and also occurred in the absence of exogenous IL-5. Preactivation of eosinophils with platelet-activating factor (PAF) significantly reduced eosinophil viability without altering the survival-reducing effects of Fas antibody treatment. In contrast, RANTES did not affect eosinophil viability or Fas antibody-induced reductions in eosinophil survival. After treatment with Fas antibody, electron microscopy of eosinophils and gel electrophoresis of DNA extracted from eosinophils demonstrated changes consistent with apoptosis. These data demonstrate that Fas antigen can modify eosinophil survival by inducing apoptosis through a pathway that is, at least in part, independent of the survival-promoting effects of IL-5.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7543306

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

1.  IL-33 enhances Siglec-8 mediated apoptosis of human eosinophils.

Authors:  Ho Jeong Na; Sherry A Hudson; Bruce S Bochner
Journal:  Cytokine       Date:  2011-11-12       Impact factor: 3.861

2.  Theophylline accelerates human granulocyte apoptosis not via phosphodiesterase inhibition.

Authors:  K Yasui; B Hu; T Nakazawa; K Agematsu; A Komiyama
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

Review 3.  Origin, regulation and physiological function of intestinal oeosinophils.

Authors:  Patricia C Fulkerson; Marc E Rothenberg
Journal:  Best Pract Res Clin Gastroenterol       Date:  2008       Impact factor: 3.043

Review 4.  Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders.

Authors:  Steven J Ackerman; Bruce S Bochner
Journal:  Immunol Allergy Clin North Am       Date:  2007-08       Impact factor: 3.479

5.  Leveraging Siglec-8 endocytic mechanisms to kill human eosinophils and malignant mast cells.

Authors:  Jeremy A O'Sullivan; Daniela J Carroll; Yun Cao; Adriano N Salicru; Bruce S Bochner
Journal:  J Allergy Clin Immunol       Date:  2017-07-20       Impact factor: 10.793

6.  Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils.

Authors:  W C Liles; P A Kiener; J A Ledbetter; A Aruffo; S J Klebanoff
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

7.  Fas-mediated apoptosis of neutrophils in sera of patients with infection.

Authors:  I E Nwakoby; K Reddy; P Patel; N Shah; S Sharma; M Bhaskaran; N Gibbons; A A Kapasi; P C Singhal
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

8.  Eosinophil survival and apoptosis in health and disease.

Authors:  Yong Mean Park; Bruce S Bochner
Journal:  Allergy Asthma Immunol Res       Date:  2010-03-24       Impact factor: 5.764

9.  Eosinophil-selective binding and proapoptotic effect in vitro of a synthetic Siglec-8 ligand, polymeric 6'-sulfated sialyl Lewis x.

Authors:  Sherry A Hudson; Nicolai V Bovin; Ronald L Schnaar; Paul R Crocker; Bruce S Bochner
Journal:  J Pharmacol Exp Ther       Date:  2009-05-19       Impact factor: 4.030

10.  Interleukin-5 priming of human eosinophils alters siglec-8 mediated apoptosis pathways.

Authors:  Esra Nutku-Bilir; Sherry A Hudson; Bruce S Bochner
Journal:  Am J Respir Cell Mol Biol       Date:  2007-08-09       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.